News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Eli Lilly and Company Fourth-Quarter Profit Meets Analysts’ Estimates
January 28, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Bloomberg -- Eli Lilly & Co. reported fourth- quarter profit of $915.4 million on higher sales of its top- seller, the antipsychotic Zyprexa, and cancer therapy Alimta.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Eli Lilly and Company
MORE ON THIS TOPIC
Mergers & acquisitions
Revolution Knows Its Worth as Merck Backs Off—For Now
January 26, 2026
·
4 min read
·
Annalee Armstrong
Funding
China’s Corxel Nabs $287M Series D1 to Bankroll GLP-1 Pill
January 23, 2026
·
1 min read
·
Tristan Manalac
Vaccines
Moderna Won’t Run Phase III Vaccine Trials as Skepticism Grows in US: Bloomberg
January 23, 2026
·
2 min read
·
Tristan Manalac
Cancer
BMS Bets $850M on Janux’s Tumor-Activated Drugs, Deepening Cancer Investments
January 22, 2026
·
2 min read
·
Tristan Manalac
